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Abstract
More than 35,000 new cases of human brucellosis were reported in 2010 by the Chinese Center for Disease Control and
Prevention. An attenuated B. melitensis vaccine M5-90 is currently used for vaccination of sheep and goats in China. In the
study, a periplasmic protein BP26 from M5-90 was characterized for its epitope reactivity with mouse monoclonal and sheep
antibodies. A total of 29 monoclonal antibodies (mAbs) against recombinant BP26 (rBP26) were produced, which were
tested for reactivity with a panel of BP26 peptides, three truncated rBP26 and native BP26 containing membrane protein
extracts (NMP) of B. melitensis M5-90 in ELISA and Western-Blot. The linear, semi-conformational and conformational
epitopes from native BP26 were identified. Two linear epitopes recognized by mAbs were revealed by 28 of 16mer
overlapping peptides, which were accurately mapped as the core motif of amino acid residues
93DRDLQTGGI
101 (position 93
to 101) or residues
104QPIYVYPD
111, respectively. The reactivity of linear epitope peptides, rBP26 and NMP was tested with
137 sheep sera by ELISAs, of which the two linear epitopes had 65–70% reactivity and NMP 90% consistent with the results
of a combination of two standard serological tests. The results were helpful for evaluating the reactivity of BP26 antigen in
M5-90.
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Introduction
Brucellae are gram-negative intracellular bacterial pathogens of
both humans and animals. More than 500,000 new cases of
human brucellosis are annually reported, which may greatly be
underestimated according to the World Health Organization [1].
Since 1995 the incidence of human brucellosis has sharply
increased in China [2]. Over 35,000 human cases were identified
in 2010 by the laboratories of Chinese Center for Disease Control
and Prevention (CDC) [3], and about 85% cases were caused by
B. melitensis infected sheep or goats [2,4]. Vaccination for animals is
considered as the most efficient way to control brucellosis. An
attenuated B. melitensis vaccine M5-90 has been mostly used for
vaccination of sheep and goats in China [2,4].
Protein BP26 is located in the periplasma of Brucella and has
been identified as an important diagnostic antigen in brucellosis
[5–7]. BP26 is highly conserved among B. abortus, B. suis, B. ovis, B.
canis, B. neotomae and B. melitensis, and was sensitive and specific for
diagnosis of Brucella infection in animals by enzyme immunoassays
(EIAs) [6–10]. Excellent protective antigen and adjuvant activity
were found with BP26 that induced elevated anibody and cellular
responses [11–13]. However, the molecular feature of BP26
antigen remains unclear. To reveal the reactivity of BP26 antigen,
this study extensively characterized the antibody recognitions of
BP26 epitopes of B. melitensis M5-90 vaccine.
Results
Production of monoclonal antibodies to B. melitensis
BP26
Recombinant periplasmic protein BP26 (rBP26) of B. melitensis
M5-90 was produced by gene expression in E. coli and used as the
immunogen for monoclonal antibody preparation. A panel of
16mer overlapping peptides, 9mer shortened peptides and
mutated peptides derived from M5-90 BP26 were synthesized
for mAb’s recognition analysis and epitope mapping (Table 1). A
total of 29 mAbs reactive to rBP26 of B. melitensis were selected
from screening of hybridomas by indirect-ELISA. Of 29 clones, 18
IgG1 (k), 1 IgG2a (k), 8 IgG2b (k), 1 IgG3 (k) and 1 IgA (k) were
identified (Table 2).
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antibodies to B. melitensis BP26
To classify mAb’s epitope recognitions, 29 mAbs were tested for
reactivity with a panel of 28 of 16mer overlapping peptides and
native BP26 containing membrane protein extracts (NMP) of M5-
90, respectively. Eleven mAbs reacted with three peptides P11,
P12 or P13 in peptide-ELISA (Figure 1A), 19 mAbs reacted with
the denatured native BP26 of NMP in Western-Blot (Figure 1B),
16 mAbs recognized non-denatured native BP26 of NMP in Dot-
ELISA (Figure 1C), and 2 mAbs were only reactive with
recombinant BP26. According to the nature of antigen, the
epitopes of natural periplasmic protein BP26 were classified into
three groups of linear, semi-conformational and conformational
epitopes, which were recognized by 11, 8 and 8 mAbs, respectively
(Table 2).
Identification of BP26 epitopes recognized by
monoclonal antibodies
Of 11 mAbs reacted with peptides (Table 1 and 2), mAbs 3D7,
3H5 and 4D9 were reactive with P11 (aa 87–102); mAbs 2A4,
2H9, 3H6 and 5F12 were reactive with P12 (aa 96–111); mAbs
1G1, 5A5, 5B12 and 7C6 were reactive with both P12 and P13 (aa
105–120) (Figure 1A). The amino acid sequences indicated that
P11 and P12 spanned the different linear epitopes, while P13
shared a partly linear epitope with P12. Seven mer amino acids
overlapped between P11 and P12 (Table 1). In order to
distinguish these two epitopes, a 16mer peptide designated as
P129 (aa 102–117) within only 1mer overlapping with P11 was
synthesized and showed reactivity similar to P12 in Peptide-ELISA
(Figure 1A).
To localize the epitopes of BP26, three truncated proteins of
rBP26-1 (aa 29–250), rBP26-2 (aa 48–131) and rBP26-3 (aa 129–
250) were tested by ELISA for reacting with 16 semi-conforma-
tional and conformational mAbs. All of those mAbs reacted with
the truncated rBP26-1 protein, 5 reacted with rBP26-2, 1 reacted
with rBP26-3 and 1 reacted with both rBP26-2 and rBP26-3
(Table 2). Other 9 mAbs were not reactive with the shorter rBP26
proteins.
Fine mapping for the linear epitopes of BP26
In order to fine mapping the two linear epitopes, a panel of six
9mer peptides with 8mer amino acid overlap shortened from P11
or P12 was tested for competitive binding to mAbs 3H5, 2A4 and
5A5 in the P11 or P12 coated plates by Peptide-ELISA,
respectively. The binding of mAb 3H5 to P11 was inhibited by
the 9mer peptide P1104 and P11 itself (Figure 2A). The core
motif of amino acid residues within P11 recognized by mAb 3H5
Table 1. Peptides derived from BP26 of B. melitensis M5-90.
Peptide Sequence Position
Group A
P01 MNTRASNFLAAS 1–12
P02 SNFLAASFSTIMLVGA 6–21
P03 TIMLVGAFSLPAFAQE 15–30
P04 LPAFAQENQMTTQPAR 24–39
P05 MTTQPARIAVTGEGMM 33–48
P06 VTGEGMMTASPDMAIL 42–57
P07 SPDMAILNLSVLRQAK 51–66
P08 SVLRQAKTAREAMTAN 60–75
P09 REAMTANNEAMTKVLD 69–84
P10 AMTKVLDAMKKAGIED 78–93
P11 KKAGIEDRDLQTGGIN 87–102
P12 LQTGGINIQPIYVYPD 96–111
P13 PIYVYPDDKNNLKEPT 105–120
P14 NNLKEPTITGYSVSTS 114–129
P15 GYSVSTSLTVRVRELA 123–138
P16 VRVRELANVGKILDES 132–147
P17 GKILDESVTLGVNQGG 141–156
P18 LGVNQGGDLNLVNDNP 150–165
P19 NLVNDNPSAVINEARK 159–174
P20 VINEARKRAVANAIAK 168–183
P21 VANAIAKAKTLADAAG 177–192
P22 TLADAAGVGLGRVVEI 186–201
P23 LGRVVEISELSRPPMP 195–210
P24 LSRPPMPMPIARGQFR 204–219
P25 IARGQFRTMLAAAPDN 213–228
P26 LAAAPDNSVPIAAGEN 222–237
P27 PIAAGENSYNV 231–241
P28 GENSYNVSVNVVFEIK 235–250
P129 NIQPIYVYPDDKNNLK 102–117
Group B
P1101 GIEDRDLQT 90–98
P1102 IEDRDLQTG 91–99
P1103 EDRDLQTGG 92–100
P1104 DRDLQTGGI 93–101
P1105 RDLQTGGIN 94–102
P1106 DLQTGGINI 95–106
P1201 INIQPIYVY 101–109
P1202 NIQPIYVYP 102–110
P1203 IQPIYVYPD 103–111
P1204 QPIYVYPDD 104–112
P1205 PIYVYPDDK 105–113
P1206 IYVYPDDKN 106–114
Group C
MutP11 KKAGIENRNLQTGGIN 87–102
MutP129 NIQPIFVFPDDKNNLK 102–117
Table 1. Cont.
Peptide Sequence Position
Group D
HCV NS3 SGLGLNAVAYYRGLDV
Four groups of synthesized peptides are listed. Group A, 27 of 16mer peptides
and 2 of 12 or 11mer peptides with 7mer overlapping deriving from BP26 of B.
melitensis M5-90. Group B, 12 of 9mer peptides with 8mer overlapping
shortening from P11 or P12. Group C, The mutated peptides basing on P11 and
P129, in which two site mutations are presented in underline bold letters. Group
D, an HCV NS3 peptide deriving from an HCV 1b strain in the laboratory. A
single letter was used for encoding amino acid (aa) sequence and aa position
was numbered from BP26 protein.
doi:10.1371/journal.pone.0034246.t001
Bp26 epitopes of Brucella melitensis
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e34246was
93DRDLQTGGI
101 (position 93 to 101 within BP26). The
bindings of mAbs 2A4 and 5A5 to P12 coated plates were
competitively inhibited by five 9mer peptides P1202, P1203,
P1204, P1205 and P1206 and P12 itself (Figure 2B and 2C).
P1203 and P1204 strongly inhibited both 2A4 and 5A5 mAbs
binding to P12, while P1202 and P1205 inhibited weakly and
P1206 did not inhibit (Figure 2B and 2C). Comparing strongly
reactive sequences of 9mer peptides and P12, the core motif of
amino acid residues within P12 was
104QPIYVYPD
111.
For further confirming those two linear epitopes of BP26, two
mutated peptides MutP11 and MutP129 were synthesized by
substituting two amino acids D93N and D95N from P11 or
substituting amino acids Y107F and Y109F from P129, respec-
tively (Table 1). The binding abilities of MutP11 and MutP129 to
11 mAbs were compared with P11 or P129. The reactivity of
MutP11 and MutP129 to mAbs was mostly lost or clearly
decreased (Figure 2D), which indicated that the two mutated
sites were critical to the epitopes
93DRDLQTGGI
101 within P11
or
104QPIYVYPD
111 within P129 for maintaining the mAb’s
recognitions except for mAbs 2H9 and 5F12.
Reactivity of linear epitope peptides and proteins of
BP26 to sheep sera
To evaluate the potential capacity of those two new epitopes for
raising antibody response in sheep, we tested 137 sheep sera with
P11-KLH and P129-KLH conjugates, rBP26 and native BP26
containing membrane protein extracts (NMP) of M5-90 by
ELISAs. Of 137 sheep sera, 59 (39 infected and 20 vaccinated)
were positive using either Standard Tube Agglutination Test
(SAT) or Rose Bengal Plate Test (RBPT). Sheep antibody
response to epitope peptides, rBP26 or NMP were analyzed in
line with the results obtained by combination of SAT and RBPT,
and their ROC curves were plotted (Figure 3). In term of
sensitivity and specificity of peptides and proteins reacting to sheep
antibodies, Figure 3 showed that the detection of reactive
antibodies in the order by NMP, rBP26, P129-KLH or P11-
KLH antigens in ELISA was closer to the result by a combination
of SAT and RBPT (P,0.001–0.002). Two linear epitope peptide
conjugates (P11-KLH and P129-KLH) were reactive to 65–70%
sheep sera in peptide-ELISA consistent with the standard
serological tests (P,0.001 and 0.002) (Figure 3A, 3B and
Table 2. Classification of mAbs reactive to the epitopes of native BP26.
MAb Isotype Peptide-ELISA Western-Blot Dot-ELISA Epitope type (aa position)
3D7 IgA (k) ++2 L (93–101)
3H5 IgG2b (k) ++2 L (93–101)
4D9 IgG2b (k) +++L (93–101)
1G1 IgG1 (k) ++2 L (104–111)
5A5 IgG2b (k) +++L (104–111)
5B12 IgG1 (k) +++L (104–111)
7C6 IgG2b (k) ++2 L (104–111)
2A4 IgG1 (k) ++2 L (104–111)
3H6 IgG1 (k) +++L (104–111)
2H9 IgG1 (k) +++L (102–117)
5F12 IgG1 (k) +++L (102–117)
1A1 IgG1 (k) 2 ++SC (29–250)
1A6 IgG1 (k) 2 ++SC (29–250)
1B7 IgG1 (k) 2 + 2 SC (29–250)
1C11 IgG1 (k) 2 + 2 SC (48–131)
4A12 IgG2b (k) 2 + 2 SC (48–131)
4D7 IgG2b (k) 2 + 2 SC (129–250)
7A8 IgG2b (k) 2 + 2 SC (48–131)
5H3 IgG1 (k) 2 + 2 SC (48–131)
3H3 IgG2b (k) 22+ C (48–131)
3C3 IgG1 (k) 22+ C (48–131, 129–250)
2C12 IgG1 (k) 22+ C (29–250)
3F9 IgG1 (k) 22+ C (29–250)
4A2 IgG1 (k) 22+ C (29–250)
4E6 IgG2a(k) 22+ C (29–250)
4E12 IgG1 (k) 22+ C (29–250)
4G1 IgG3 (k) 22+ C (29–250)
3H2 IgG1 (k) 222Un-classified
4E4 IgG1 (k) 222Un-classified
MAbs were individually tested to react with the synthetic peptides by Peptide-ELISA, denatured and non-denatured native BP26 containing membrane protein extracts
of M5-90 (NMP) by Western-Blot or Dot-ELISA, respectively. According to the nature of antigen, the epitopes recognized by mAbs were classified into three statuses of
linear (L), semi-conformational (SC) and conformational (C) epitopes. Un-classified indicates artificial epitopes of recombinant BP26.
doi:10.1371/journal.pone.0034246.t002
Bp26 epitopes of Brucella melitensis
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Bindings of mAbs to 16mer overlapping peptides in Peptide-ELISA. Twenty nine of 16mer overlapping peptides spanning the entire sequence of
BP26 were coated to the plates with 5 mg/ml in CBS buffer (pH 9.6). The peptides bound plates were tested with 29 mAb supernatants of
hybridomas. An HCV NS3 peptide coated wells were used as negative-controls. Cut off was defined above 2.1 folds of OD value to negative control.
The dot line indicates the level of cut off. (B) Reactivity of mAbs to the SDS denatured native BP26 of NMP in Western-Blot. (C) Reactivity of mAbs to
non-denatured native BP26 of NMP in Dot-ELISA. NC, a negative control of an un-related mAb to HCV rNS3.
doi:10.1371/journal.pone.0034246.g001
Figure 2. Competitive binding of mAb to the 16mer peptide inhibited by 9mer or mutated peptides in Peptide-ELISA. (A) P11 and
mAb 3H5; (B) P12 and mAb 2A4; (C) P12 and mAb 5A5. A volume of 50 ml of supernatants of mAb 2A4, 3H5 or 5A5 cell cultures was pre-mixed with
50 ml of each 9mer peptide dilution (P1101 to P1106 or P1201 to P1206 and control peptides) at concentration of 0, 2, 4, 8, 16 and 32 mg/ml. A
volume of 100 ml of the mAb and peptide mixture was added to the 16mer peptides P11 or P12 coated wells. P11 or P12 was used as an inhibitive
(positive) control (PC), respectively. One HCV NS3 peptide was used a non-inhibitive (negative) control (NC). (D) Binding of mAbs to P11 and P129
compared with their mutated peptides MutP11 and MutP129.
doi:10.1371/journal.pone.0034246.g002
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dominant in M5-90 vaccine elicited antibodies. By using the
antigens rBP26 and NMP, the ELISA had higher sensitivity and
specificity for detection of antibodies to Brucella infection or
vaccination in sheep, for which 83% or 90% were identical to the
results from the combined SAT and RBPT (P,0.001) (Figure 3C,
3D and Table 3), suggesting that NMP could be a potential
antigen in immunoenzyme assay (EIA) for diagnosis or quantifi-
cation of antibodies to Brucella in infected/vaccinated animals.
Discussion
The live attenuated Brucella melitensis vaccine strain Rev.1 is
recognized worldwide as the best vaccine available against
brucellosis in sheep and goats [14–16]. Currently a similar
attenuated B. melitensis vaccine strain M5-90 is mostly used in
China [17], which is also considered to be an important strategy
leading to the decline of brucellosis incidence in humans and
animals between the 1970 and 1990s in China [2]. However, the
antibody responses raised by those two live vaccines are difficult to
distinguish from naturally Brucella infected animals using the
conventional serological tests. In addition, those attenuated
vaccines still keep residual virulence for humans and may result
Figure 3. Reactivity of sheep sera to linear epitope peptides, rBP26 and NMP of B. melitensis in ELISAs. The receiver operating
characteristic (ROC) curves were plotted using the SPSS software version 13.0. According to optimal cutoff values by the highest sum of sensitivity
and specificity, the areas under ROC curves for antibody responses in sheep sera by ELISAs were compared with the results by a combination of two
standard serological tests. P value was calculated for comparing the differences between areas under ROC curve and reference (0.5) by the
Kolmogorov-Smirnov Z analysis.
doi:10.1371/journal.pone.0034246.g003
Table 3. Evaluation for reactivity of peptides and proteins of
B. melitensis to sheep sera in ELISAs.
Antigen P11-KLH P129-KLH rBP26 NMP
Sera dilution 1/20 1/20 1/200 1/200
Sensitivity (%) 68.3 83.3 84.5 89.7
Specificity (%) 62.3 59.7 81.4 90.0
Agreement (%) 65.0 70.1 82.8 89.8
PPV (%) 58.5 61.7 79.0 88.1
NPV (%) 71.6 82.1 86.4 91.3
True positive (a) 41 50 49 52
False positive (b) 29 31 13 7
False negative (c) 19 10 9 6
True negative (d) 48 46 57 63
Total 137 137 128 128
Reactivity of epitope peptides and proteins of B. melitensis to 137 sheep sera
were tested, and the predictive values in ELISAs were evaluated in line with the
combined SAT and RBPT. PPV, positive predictive value; NPV, negative
predictive value. Sensitivity=a/(a+c); Specificity=d/(b+d); agreement=(a+d)/
(a+b+c+d); PPV=a/(a+b); NPV=d/(c+d).
doi:10.1371/journal.pone.0034246.t003
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mutant obtained by deleting BP26 of Rev.1 was developed [20],
which was found protective against B. melitensis in sheep or B. ovis in
rams [21,22]. In contrast, the BP26-deleted M5-90 mutant did not
conserve the protective immunity from its parental vaccine strain
[23,24], which suggested that BP26 might be associated with
protective efficacy in M5-90 vaccine.
Previous data demonstrated that BP26 provided a strong
protection antigen within Rev. 1 inducing not only high IgG1
titers but also cellular response of IFN-c, IL-4, IL-5 and IL-6 [11–
13]. In a separate study, we determined the IFN-c response
specific to T cell epitopes of BP26 in sheep (data not shown),
which also indicated that BP26 was responsible for the mixed Th
cell response. The 62% (18/29) IgG1 of murine mAbs obtained in
the present study, it suggested that BP26 might be associated with
Th2 cytokine responses. Additionally the presence of BP26
enhanced antibody response to the chaperone protein, trigger
factor (TF) [11–13], suggested that BP26 and other relevant
proteins such as TF and omp31 might be involved in protective
immunity to Brucella infections [25–28].
Molecular epitopes of BP26 to both B cells and T cells have not
been explored extensively. A region of amino acid residues
position 55 to 152 within a truncated BP26 protein had been
previously found reactive with two monoclonal antibodies, but the
epitopes recognized had not been identified [10]. In this study, 29
mAbs were produced against recombinant BP26 and 27 of them
were reactive with native BP26 containing membrane protein
extracts (NMP) of B. melitensis M5-90. Two linear epitopes were
initially discovered using 28 overlapping peptides spanning the
whole sequence of BP26. The core motifs of those two linear
epitopes were accurately defined as amino acid sequences
93DRDLQTGGI
101 and
104QPIYVYPD
111 recognized by 11 of
29 mAbs, indicating that both were dominant epitopes within the
BP26 antigen. Additionally the semi-conformational and confor-
mational epitopes of native BP26 recognized by two groups of
each eight mAbs were identified. All 16 mAbs were reactive to the
truncated BP26-1 protein (aa 29–250) that did not contain 28
amino acid signal peptide. Four semi-conformational and one
conformational epitopes were approximately localized between aa
48–131, and one semi-conformational epitope was identified
between aa 129–250, which suggested that amino acids 48–131
within BP26 contained major semi-conformational and confor-
mational epitopes. MAb 3C3 recognized both aa 48–131 and aa
129–250 of truncated rBP26 proteins, which indicated the
conformational epitope was structurally formed by those two
parts of BP26 protein. Other un-identified 9 mAbs might be
involved in more complicated epitope recognitions, mostly
conformational.
Recombinant BP26 was investigated for diagnosis of brucellosis
in sheep and goats [6,7,10,29,30]. By ELISA, we compared the
reactivity of sheep sera to two linear epitope peptides (P11-KLH
and P129-KLH), rBP26 and NMP in line with the combination of
SAT and RBPT. Peptides P11 and P129 reacted with sera of
Brucella infected or M5-90 vaccinated sheep, which were 65% or
70% consistent with results of the combined SAT and RBPT. The
reactivity of two linear epitopes of BP26 to mAbs could be
inactivated by mutations of two critical amino acids, which
suggested that molecular modification for BP26 epitopes of M5-90
could be genetically realized without altering the protein structure.
Compared with rBP26, the NMP appeared more sensitive and
specific in ELISA for detection of antibodies to Brucella from sheep,
and had 90% agreement with the combination of SAT and RBPT.
In this study, we identified linear, semi-conformational and
conformational B cell epitopes within B. melitensis BP26 and finally
mapped two novel linear epitopes reacting with antibodies in
sheep. Taking together with T cell epitopes of BP26, the results
were helpful for evaluation of BP26 antigen function within
vaccine M5-90.
Materials and Methods
Ethics statement
All animal care and procedures were in accordance with
national and institutional policies for animal health and well-being.
Mouse experimentation and Sheep blood sample collection and
field study were approved by Southern Medical University (SMU)
Animal Care and Use Committee (permit numbers: NFYY-2008-
043 and NFYY-2010-076). All mouse surgery was performed
under anesthesia, and all efforts were made to minimize suffering
of animals.
Brucella strain and serum
Attenuated B. melitensis vaccine strain M5-90 was cultured in the
broth of Trypticase Soy medium (TSB) supplemented with 0.1%
(w/v) yeast extract, which was used for extraction of DNA or
membrane proteins. A total of 137 sheep serum samples (117
random, 20 vaccinated) were collected from the farms in Brucella
epidemic area of Shihezi, Xinjiang or provided by the Chinese
Center for Disease Control and Prevention, Beijing, China. Sera
were tested by Standard Tube Agglutination Test (SAT) and Rose
Bengal Plate Test (RBPT), and positive samples were confirmed by
either or both tests.
Recombinant periplasmic protein BP26
By using pET-28a plasmid, recombinant entire BP26 (rBP26),
truncated rBP26-1 (aa 29–250), truncated rBP26-2 (aa 48–131)
and truncated rBP26-3 (aa 129–250) were expressed in E. coli
induced for 4 hours by 1 mM Isopropyl-1-thio-D-galactopylor-
anoside (IPTG) at 37uC. Soluble rBP26 was purified by Ni-NTA
agarose (GE Healthcare, Milwaukee, Wisconsin, United States)
and analyzed by Sodium Dodecyl Sulfate–Polyacrylamide Gel
Electrophoresis (SDS-PAGE).
Peptides and conjugates
A panel of 44 peptides was synthesized by a commercial
company (Chinese Peptide Company, Hangzhou, Zhejiang,
China). Twenty-eight of 16mer peptides with 7mer overlap were
designated as P01 to P28 spanning the 250 amino acids of the
entire BP26 periplasmic protein. Twelve of 9mer peptides
shortened from P11 and P12 were designated as P1101 to 06 or
P1201 to 06. One of 16mer peptide was designated as P129, as it’s
only the first amino acid overlapped with the C-terminal amino
acid of P11. Two mutated P11 and P129 were designated as
MutP11 and MutP129, respectively. One HCV NS3 peptide is
used as a negative control. All peptides had above 90% purity.
P11 and P129 conjugates coupled with keyhole limpet
hemocyanin (P11-KLH and P129-KLH) were prepared by a
commercial company (Chinese Peptide Company, Hangzhou,
Zhejiang, China).
B. melitensis M5-90 membrane protein extraction
Native BP26 containing membrane proteins (NMP) were
extracted from the attenuated B. melitensis strain M5-90 by
ReadyPrep Protein Extraction Kit (membrane II) (Bio-Rad
Laboratories, Hercules, California, United States). The cells were
sonicated in Lysis buffer to fractionate and isolate membrane
proteins by sodium carbonate extraction methods applied in the
kit [31]. The carbonate treated membranes were collected by
Bp26 epitopes of Brucella melitensis
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average of 100 000 g for 1 h at 4 C. The membrane pellet was
washed and resuspended in PBS (50 mM, pH 7.2), and analyzed
by SDS-PAGE.
Mouse immunization
Three 6-weeks old BALB/c female mice were housed at the
Laboratory Animal Center, Southern Hospital, Southern Medical
University, Guangzhou, China. Mice were inoculated with rBP26
antigens for three times at 2-week intervals. The first subcutaneous
injection contained 100 mg of rBP26 in a final volume of 100 ml
(100 mg/100 ml) of complete Freund adjuvant (Sigma-Aldrich, St
Louis, Missouri, United States). The second subcutaneous
injection was 50 mg/100 ml rBP26 antigen with incomplete
Freund adjuvant (Sigma-Aldrich, St Louis, Missouri, United
States). The final boost was intraperitoneally injected with 50 mg
of rBP26 in 100 ml of PBS. The antibody titers to rBP26 were
determined on day 3 after the final injection, and the best
responding mice were sacrificed and the spleens were obtained.
Pre- and post-immunization sera were collected and used as
negative or positive controls for screening monoclonal antibodies
(mAbs).
Monoclonal antibody production
The spleen cells of rBP26 immunized mice were fused with
SP2/0 myeloma cells in a ratio of 5:1 by polyethylene glycol 4000
(PEG 4000, Sigma-Aldrich, St Louis, Missouri, United States).
Mouse myeloma cell line SP2/0 was provided by the laboratory,
which was originated from Division of Transfusion Medicine,
Department of Haematology, University of Cambridge, UK [32].
Antibody-producing hybridomas were primarily screened by an
indirect ELISA with 3 mg/ml of rBP26 coated Nunc Immuno
microtiter plates (JET BIOFIL Bio-filtration Products Co. Ltd,
Guangzhou, Guangdong, China). Single hybridoma cell was
cloned by limiting dilution in RPMI1640 (Hyclone Lab Inc,
Nampa, Idaho, United States) supplemented with 20% fetal calf
serum (PAA Laboratories, Tawasu, Makira-Ulawa, Solomon
Islands, Australia), 100 IU/ml penicillin and 100 mg/ml strepto-
mycin. Supernatants of cloned hybridoma cultures were collected
for mAb analyses. MAb Isotyping was performed by IsoQuick
Strips for Mouse Monoclonal Isotyping (Sigma-Aldrich, St Louis,
Missouri, United States) or Mouse Monoclonal Antibody Isotyp-
ing Kit (Hycult Biotech Inc, Uden, Netherlands). One mAb (IgG 1
kappa) to recombinant HCV NS3 (rNS3) was used as an un-
related negative control.
Peptide-ELISA
Nunc Immuno microtiter plates were coated with 5 mg/ml of
16mer peptides in 0.1 M carbonate buffer (pH 9.6) and were
incubated overnight at 4uC as described previously [32]. Plates
were washed four times with phosphate-buffered saline (PBS,
pH 7.2) containing 0.05% Tween-20 (PBST) and blocked in 4%
bovine serum albumin (BSA) PBS buffer for 1 h at 37uC. For
detecting mAb reactivity to peptides, 100 ml of hybridoma
supernatant was added into each well of plates; goat anti-mouse
IgG and IgM horseradish peroxidase (HRP)-conjugate (Rockland
Immunochemicals Corp, Boyertown, Pennsylvania, United States)
was used as secondary antibody, and 3,39-5,59_tetramethylbenzi-
dine (TMB) was used as the colorimetric substrate. The reaction
was determined by a microplate reader at the absorption of
450 nm (Model 550, Bio-Rad Laboratories, Hercules, California,
United States).
To map epitopes accurately, a panel of 9mer shorter peptides
derived from P11 or P12 was synthesized for competitive binding
to mAbs in peptide-ELISA. An HCV NS3 peptide was used as
negative control.
Western-Blot
The rBP26 or native BP26 containing membrane protein
extracts (NMP) of M5-90 were denatured and electrophoresed on
SDS-PAGE, then transferred to Polyvinylidene Fluoride mem-
branes (PVDF membranes, Millipore, Billerica, Massachusetts,
United States), and finally blocked in TBST containing 5% non-
fat dry milk for 2 h. Protein bound membranes were saturated
with the diluted supernatants of mAbs cultures for 1 h at room
temperature. The membranes were washed three times with
TBST and incubated with 1:10000 diluted goat anti-mouse IgG
and IgM HRP-conjugate in TBST for 1 h. MAb bound
membranes were washed and visualized by adding immunochem-
iluminescence reagent (ECL, Millipore, Billerica, Massachusetts,
United States). An unrelated mAb to HCV rNS3 was used as
negative control.
Dot-ELISA
PVDF membranes (8 mm68 mm) were soaked in methanol for
1 min and then dried at room temperature. One microliter of
native BP26 containing membrane protein extract (NMP) of M5-
90 was dropped onto the center of each membrane and dried at
room temperature. MAbs of cloned supernatant cultures were
added to NMP on the membranes and the bound mAbs were
detected by goat anti-mouse HRP-conjugate. The membranes
were visualized by adding diaminobenzidine (DAB) substrate for
color development. An unrelated mAb to HCV rNS3 was used as
negative control.
Statistical analysis
The overall sensitivity of Peptide-ELISA, rBP26-ELISA, NMP-
ELISA for detection of antibodies to Brucella from sheep sera were
calculated using receiver operating characteristic (ROC) curves.
Optimal cutoff values were defined using the highest sum of
sensitivity and specificity. For each optimal cutoff value, sensitivity,
specificity, positive predictive value (PPV) and negative predictive
value (NPV) were calculated [33]. P value was obtained for
comparing the differences between the areas under ROC curve
(AUC) and reference (0.5) by the Kolmogorov-Smirnov Z analysis
in SPSS software version 13.0.
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